Ipamorelin vs Tesamorelin

Ipamorelin and tesamorelin are both studied for their effects on growth hormone release, but they work through different receptors and have very different regulatory histories.

Ipamorelin is a small synthetic pentapeptide that acts on the ghrelin receptor, also called the growth hormone secretagogue receptor. Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH) that acts on the GHRH receptor. Tesamorelin is FDA-approved and marketed as Egrifta for a specific indication, while ipamorelin is a research compound and not an approved medicine in the US. That contrast matters for researchers: tesamorelin brings a documented clinical development history, while ipamorelin is valued as a selective tool for probing the ghrelin receptor pathway. This page compares the two on mechanism, structure, research status and laboratory handling to help you decide which fits your research question. PRIME supplies both as lyophilized powder for laboratory research use only.

Ipamorelin: a selective ghrelin receptor agonist

Ipamorelin is a synthetic pentapeptide in the growth hormone secretagogue family. It acts on the ghrelin receptor (GHS-R1a), the receptor activated by the natural hormone ghrelin, and stimulates growth hormone release from the pituitary through that pathway rather than through the GHRH receptor.

Its main point of interest in research is selectivity. Earlier secretagogues were associated in animal studies with rises in other hormones, such as cortisol and prolactin, alongside growth hormone. Ipamorelin was reported to stimulate growth hormone release with comparatively little effect on those hormones, which made it a cleaner tool for studying the ghrelin receptor route to growth hormone release.

Research areas that have been investigated include:

• Ghrelin receptor signaling in the pituitary
• Selectivity of growth hormone release
• Bone models in animals
• Gastrointestinal motility models
• Interaction with GHRH analogs

Ipamorelin is a research compound and is not an approved medicine in the US. Its clinical literature is limited, so most of what is known comes from preclinical work.

PRIME supplies ipamorelin as a lyophilized powder for in-vitro and preclinical research. It is sold for laboratory research use only and is not for human consumption.

Tesamorelin: an approved GHRH analog

Tesamorelin is a synthetic analog of growth hormone-releasing hormone. Unlike shorter analogs based on the first 29 amino acids, it uses the full 44-amino-acid GHRH sequence, with a chemical modification at the N-terminus that makes it more resistant to breakdown by enzymes. It acts on the GHRH receptor in the pituitary, stimulating growth hormone release through the same pathway as the natural hormone.

Tesamorelin has a regulatory history that most research peptides lack. It is FDA-approved and marketed as Egrifta for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy. Its clinical program means there is a substantial body of published work on how it behaves.

Research areas that have been investigated include:

• GHRH receptor signaling and pituitary function
• Visceral adipose tissue and body composition
• The growth hormone and IGF-1 axis
• Liver fat in clinical research settings

For laboratory work, that clinical background provides a useful reference point when interpreting preclinical findings on GHRH receptor agonism.

PRIME supplies tesamorelin as a lyophilized powder for in-vitro and preclinical research. The material PRIME sells is for laboratory research use only and is not for human consumption.

The receptor pathway is the main deciding factor, followed by how much existing literature your study needs to build on. Both compounds ultimately act on growth hormone release, but they reach it from different starting points in the pituitary.

Ipamorelin fits studies of the ghrelin receptor pathway, especially where selectivity matters and researchers want to limit changes in other pituitary and adrenal hormones. It is also used in bone and gastrointestinal models.

Tesamorelin fits studies of the GHRH receptor pathway, particularly work on visceral fat, body composition and the IGF-1 axis. Its approval history gives researchers a documented clinical reference that newer or unapproved GHRH analogs lack.

For a shorter GHRH analog compared with ipamorelin, see the CJC-1295 vs ipamorelin comparison. For full background on each compound, read the ipamorelin research guide and the tesamorelin research guide. Every batch has a published certificate of analysis on the lab results page.

For laboratory research use only. Not for human consumption.